CervoMed is trading 12.4% down at $1.94 after its 159-patient RewinD-LB Phase 2b study failed to confirm the earlier Phase 2a result on the primary measure, change in CDR-SB, across the full intention-to-treat population.

  • Results were published October 29; some analyses were more favorable among participants with low Alzheimer’s co-pathology.
  • The release also cited supportive MRI and biomarker findings. The broader market is weaker, but trial news is the direct catalyst.